BamSEC and AlphaSense Join Forces
Learn More

MoonLake Immunotherapeutics

NASDAQ: MLTX    
Share price (3/26/25): $38.39    
Market cap (3/26/25): $2.457 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.4
from 10-Q 23 pages Share Participation Plan 1 Employee Share Participation Plan MoonLake Immunotherapeutics AG, Zug, Switzerland Share Participation Plan 2
12/34/56
EX-10.3
from 10-Q 27 pages Employee Stock Option Plan Dated June 15, 2023 of MoonLake Immunotherapeutics AG, Zug, Switzerland Employee Stock Option Plan 2
12/34/56
EX-10.2
from 10-Q 13 pages [***] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because the Information (I) Is Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Novation, Amendment, and Restatement of License Agreement
12/34/56
EX-10.1
from 10-Q 48 pages MoonLake Immunotherapeutics Class a Ordinary Shares (Par Value $0.0001 Per Share) Sales Agreement
12/34/56
EX-10.25
from 10-K 7 pages MoonLake Immunotherapeutics 2022 Equity Incentive Plan Grant Notice for Nonqualified Stock Options
12/34/56
EX-10.7
from S-8 22 pages Employee Share Participation Plan MoonLake Immunotherapeutics AG, Zug, Switzerland
12/34/56
EX-10.4
from S-8 27 pages Employee Stock Option Plan MoonLake Immunotherapeutics AG, Zug, Switzerland
12/34/56
EX-10.12
from S-1/A 42 pages Clinical and Commercial Manufacturing Agreement Dated 1 July, 2021 by and Between Richter-Helm Biologics Gmbh & Co. Kg and MoonLake Immunotherapeutics AG
12/34/56
EX-10.8
from S-1/A 5 pages Dated [__] (1) Helix Acquisition Corp. (2) [__] Subscription Agreement
12/34/56
EX-10.33
from 8-K 6 pages MoonLake Immunotherapeutics 2022 Equity Incentive Plan Stock Option Agreement
12/34/56
EX-10.8
from 8-K 19 pages MoonLake Immunotherapeutics 2022 Equity Incentive Plan
12/34/56
EX-10.7
from 8-K 22 pages Subscription Agreement
12/34/56
EX-10.5
from 8-K 25 pages Amended and Restated Registration Rights Agreement
12/34/56
EX-10.2
from 8-K 47 pages Certain Personally Identifiable Information Contained in This Document, Marked by Brackets as [***], Has Been Omitted From This Exhibit Pursuant to Item 601(a)(6) Under Regulation S-K
12/34/56
EX-10.1
from 8-K 3 pages Promissory Note
12/34/56
EX-10.1
from 425 3 pages Promissory Note
12/34/56
EX-10.13
from S-1/A 3 pages Assignment
12/34/56
EX-10.12
from S-1/A 2 pages Amendment No.2 to the Clinical and Commercial Manufacturing Agreement
12/34/56
EX-10.11
from S-1/A 42 pages Clinical and Commercial Manufacturing Agreement Dated October 15th, 2018 by and Between Richter-Helm Biologics Gmbh & Co. Kg and Merck Kgaa I
12/34/56
EX-10.10
from S-1/A 4 pages Certain Personally Identifiable Information Contained in This Document, Marked by Brackets as [***], Has Been Omitted From This Exhibit Pursuant to Item 601(a)(6) Under Regulation S-K. April 29, 2021 Re: Effect of Assignment of the License Agreement Upon a Termination of Initial License Agreement Dear Madams and Sirs
12/34/56